Opinion|Videos|July 17, 2024
Final Thoughts on CSPC
Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How do you foresee the early treatment paradigm for CSPC evolving in the coming years?
- Are there other novel agents you're excited about in development?
- How will their availability impact treatment sequencing strategies?
Advertisement
Related to this article
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Calculating the Real Cost of False Positive Findings in Cancer Screening
4
China's NMPA Approves Pirtobrutinib Across CLL
5